LAG3 and lung carcinoma: Radiotherapy combined with NBTXR3 plus simultaneous blockade of three immune checkpoint receptors, PD1, LAG3 and TIGIT, was evaluated in an animal model of lung cancer resistant to anti-PD1 therapy.